• Gyre Therapeutics held its annual stockholders meeting on June 10, 2026.
• Stockholders voted in favor of seating two Class II director nominees, with terms running through the 2029 annual meeting.
• Stockholders ratified Grant Thornton Zhitong Certified Public Accountants LLP as independent registered public accounting firm for 2026.
• Stockholders authorized issuance of common shares upon conversion of the Series B Convertible Preferred Stock; conversion itself was not reported as completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-025324), on June 16, 2026, and is solely responsible for the information contained therein.